Nicholas Bagley, JD, says immediate effects of the ruling have been modest so far.
Nicholas Bagley, JD, professor at Michigan Law, University of Michigan, spoke to The American Journal of Managed Care® about the Braidwood v Becerra ruling and the uncertainty around decisions that will follow if it is upheld.
Transcript
What are the immediate effects of the ruling in Braidwood v Becerra?
The decision isn't going to have an immediate or dramatic effect, and that's for a couple of reasons. First, and most importantly, I think most employers and insurers are kind of in a watching and waiting mood. They're looking to see what's going to happen with this case on appeal. I think very few, if any, [are going to be making serious] or sweeping changes to their coverage choices. That may actually end up being the case, even if the plaintiffs win—that there will be a relatively small number of employers that really change up what they're doing. But there's a fair amount of uncertainty around that and what kinds of decisions they’ll make if the decision is eventually upheld.
The government has already appealed the judge's decision and asked the US Court of Appeals for the Fifth Circuit to put a hold on his decision while the Fifth Circuit considers it. That effort to get a state pending appeal has been opposed by the plaintiffs who are also going to take an appeal of their own. But in the meantime, I think, right now, we are mostly in a waiting mode. The longer this drags on, the more employers and insurers may decide that they want to try to change their offerings. But for now, it seems that their response has been pretty modest.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More